CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,242,786
- in 10 filings, $10.6M under 10b5-1 plans
Net −$33,242,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-05 | Drape Eric Executive VP Global Operations | Option exercise · Restricted Share Units 10b5-1 | −22,576 | 22,576 | ||
| 2024-03-05 | Drape Eric Executive VP Global Operations | Option exercise · Restricted Share Units 10b5-1 | −55,226 | 0 | ||
| 2024-03-05 | Daniell Richard Exec. VP, European Commercial | Option exercise 10b5-1 | +22,576 | 92,346 | ||
| 2024-03-05 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −22,576 | $13.52 | $305K | 69,770 |
| 2024-03-05 | Daniell Richard Exec. VP, European Commercial | Option exercise 10b5-1 | +55,226 | 124,996 | ||
| 2024-03-05 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −26,053 | $13.52 | $352K | 98,943 |
| 2024-03-05 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units 10b5-1 | −22,576 | 22,576 | ||
| 2024-03-05 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units 10b5-1 | −55,226 | 0 | ||
| 2024-03-05 | Conway Vikki L See "Remarks" | Option exercise 10b5-1 | +4,954 | 16,646 | ||
| 2024-03-05 | Conway Vikki L See "Remarks" | Sale 10b5-1 | −1,427 | $13.52 | $19K | 15,219 |
| 2024-03-05 | Conway Vikki L See "Remarks" | Option exercise · Restricted Share Units 10b5-1 | −4,954 | 4,957 | ||
| 2024-03-05 | Sabag Mark EVP, International Markets | Option exercise | +23,764 | 424,457 | ||
| 2024-03-05 | Sabag Mark EVP, International Markets | Option exercise | +58,133 | 482,590 | ||
| 2024-03-05 | Sabag Mark EVP, International Markets | Sale | −100,000 | $13.52 | $1.4M | 382,590 |
| 2024-03-05 | Sabag Mark EVP, International Markets | Option exercise · Restricted Share Units | −23,764 | 23,765 | ||
| 2024-03-05 | Sabag Mark EVP, International Markets | Option exercise · Restricted Share Units | −58,133 | 0 | ||
| 2024-03-05 | Weiss Amir Chief Accounting Officer | Option exercise | +3,564 | 33,314 | ||
| 2024-03-05 | Weiss Amir Chief Accounting Officer | Option exercise · Restricted Share Units | −3,564 | 3,566 | ||
| 2024-03-04 | McAvoy David R. EVP, Chief Legal Officer | Grant or award · Restricted Share Units | +66,964 | 66,964 | ||
| 2024-03-04 | Conway Vikki L See "Remarks" | Sale 10b5-1 | −1,490 | $13.37 | $20K | 6,617 |
Page 22 of 76 · 1,517 trades